The Timely Diagnosis and Treatment of Alzheimer’s Disease: Microsimulating Cost-Effectiveness in the Czech Republic

Demografie ◽  
2021 ◽  
Vol 63 (4) ◽  
pp. 216-225
Author(s):  
Hana M. Broulíková ◽  
Matěj Kučera ◽  
Markéta Arltová
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Czech Republic ◽  
Cost Effectiveness ◽  
Early Stage ◽  
Dominant Strategy ◽  
Diagnosis And Treatment ◽  
Net Benefit ◽  
The Czech Republic ◽  
Timely Diagnosis

Using a microsimulation model, this study evaluates the cost-effectiveness of a hypothetical policy that would increase diagnosis and treatment availability for people at an early stage of Alzheimer’s disease in the Czech Republic. If widely available, timely diagnosis and treatment would represent a dominant strategy bringing net benefit of EUR 13,751 per lifetime of each person living with this disease.

scholarly journals Anticipated Social and Healthcare Economic Burden of People with Alzheimer’s Disease in Two Selected Regions of the Czech Republic

Healthcare ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 433
Author(s):  
Petra Maresova ◽  
Lenka Komarkova ◽  
Jitka Kuhnova ◽  
Richard Cimler ◽  
Peter Pazitny ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Czech Republic ◽  
Prediction Model ◽  
Economic Burden ◽  
Healthcare Services ◽  
The Czech Republic ◽  
Financial Pressure

Increasing life expectancy in modern society is undoubtedly due to improved healthcare, scientific advances in medicine, and the overall healthy lifestyle of the general population. However, this positive trend has led to an increase in the number of older people with a growing need for a sustainable system for the long-term care of this part of the population, which includes social and health services that are essential for a high quality of life. Longevity also brings challenges in the form of a polymorbid geriatric population that places financial pressure on healthcare systems. Regardless, one disease dominates the debate about financial sustainability due to the increasing numbers of people diagnosed, and that is Alzheimer’s disease (AD). The presented paper aims to demonstrate the economic burden of social and healthcare services. Data from two regions in the Czech Republic were selected to demonstrate the potential scope of the problem. The future costs connected with AD are calculated by a prediction model, which is based on a population model for predicting the number of people with AD between 2020 and 2070. Based on the presented data from the two regions in the Czech Republic and the prediction model, several trends emerged. There appears to be a significant difference in the annual direct costs per person diagnosed with AD depending on the region in which they reside. This may lead to a significant inequality of the services a person can acquire followed by subsequent social issues that can manifest as a lower quality of life. Furthermore, given the prediction of the growing AD population, the costs expressed in constant prices based on the year 2020 will increase almost threefold during the period 2020–2070. The predicted threefold increase will place additional financial pressure on all stakeholders responsible for social and healthcare services, as the current situation is already challenging.

Fluoxetine Protects against Dendritic Spine Loss in Middle-aged APPswe/PSEN1dE9 Double Transgenic Alzheimer’s Disease Mice

2020 ◽  
Vol 17 (1) ◽  
pp. 93-103 ◽  
Author(s):  
Jing Ma ◽  
Yuan Gao ◽  
Wei Tang ◽  
Wei Huang ◽  
Yong Tang
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Dendritic Spines ◽  
Dendritic Spine ◽  
Early Stage ◽  
Learning Ability ◽  
Middle Aged ◽  
Protein Levels ◽  
Spine Pathology ◽  
The Impact

Background: Studies have suggested that cognitive impairment in Alzheimer’s disease (AD) is associated with dendritic spine loss, especially in the hippocampus. Fluoxetine (FLX) has been shown to improve cognition in the early stage of AD and to be associated with diminishing synapse degeneration in the hippocampus. However, little is known about whether FLX affects the pathogenesis of AD in the middle-tolate stage and whether its effects are correlated with the amelioration of hippocampal dendritic dysfunction. Previously, it has been observed that FLX improves the spatial learning ability of middleaged APP/PS1 mice. Objective: In the present study, we further characterized the impact of FLX on dendritic spines in the hippocampus of middle-aged APP/PS1 mice. Results: It has been found that the numbers of dendritic spines in dentate gyrus (DG), CA1 and CA2/3 of hippocampus were significantly increased by FLX. Meanwhile, FLX effectively attenuated hyperphosphorylation of tau at Ser396 and elevated protein levels of postsynaptic density 95 (PSD-95) and synapsin-1 (SYN-1) in the hippocampus. Conclusion: These results indicated that the enhanced learning ability observed in FLX-treated middle-aged APP/PS1 mice might be associated with remarkable mitigation of hippocampal dendritic spine pathology by FLX and suggested that FLX might be explored as a new strategy for therapy of AD in the middle-to-late stage.

Sign in / Sign up

Export Citation Format

Share Document